You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 159 No. 10, May 24, 1999 TABLE OF CONTENTS
  Archives
  •  Online Features
  Special Article
 This Article
 •Full text
 •PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on ISI (15)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Topic Collections
 •Immunologic Disorders
 •Health Policy
 •Alert me on articles by topic

Clinical Progress and the Future of HIV Exceptionalism

Ronald Bayer, PhD

Arch Intern Med. 1999;159:1042-1048.

In the 18 years since the first cases of the acquired immunodeficiency syndrome (AIDS) were reported by the Centers for Disease Control and Prevention (CDC), the epidemic has undergone profound transformations, and so, too, has the sociomedical context within which public health policy is fashioned and implemented. The early years of neglect and panic were also characterized by relative therapeutic impotence and deep uncertainty about the epidemiological course the new threat would take. In the United States and in other economically advanced nations, the threat of contracting the human immunodeficiency virus (HIV) has abated. The incidence of infection has declined, and the prevalence of infection has stabilized and, in some instances, begun to fall. The pattern of HIV spread, where it has continued, has been dramatically circumscribed to marginalized populations.1 The panic of the mid-1980s has passed, and in many nations, AIDS has lost its salience as a public issue. A sense of therapeutic impotence no longer prevails, and a new mood of triumphalism has taken hold. How have these crucial changes affected AIDS policies in America?


From the Division of Sociomedical Sciences, Columbia University School of Public Health, New York, NY.



THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Routine HIV Testing in Dental Practice: Can We Cross the Rubicon?
Vernillo and Caplan
J Dent Educ 2007;71:1534-1539.
ABSTRACT | FULL TEXT  

HIV exceptionalism, CD4+ cell testing, and conscientious subversion
Jansen
J. Med. Ethics 2005;31:322-326.
ABSTRACT | FULL TEXT  

HIV-Related Stigma and Knowledge in the United States: Prevalence and Trends, 1991-1999
Herek et al.
Am. J. Public Health 2002;92:371-377.
ABSTRACT | FULL TEXT  

Genetic Exceptionalism vs. Paradigm Shift: Lessons from HIV
Ross
J Law Med Ethics 2001;29:141-148.
 

What Lessons Can We Learn from the Exceptionalism Debate (Finally)?
Lazzarini
J Law Med Ethics 2001;29:149-151.
 

Genetic Exceptionalism vs. Paradigm Shift: Lessons from HIV
Ross
J Law Med Ethics 2001;29:141-148.
 

What Lessons Can We Learn from the Exceptionalism Debate (Finally)?
Lazzarini
J Law Med Ethics 2001;29:149-151.
 





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1999 American Medical Association. All Rights Reserved.